Hepion Pharmaceuticals, Inc. announced that the Data and Safety Monitoring Board (DSMB) has met to review the current data for the ASCEND-NASH Phase 2b trial and has issued a study may proceed without modification clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, EKGs, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial. Hepion is on track to complete enrollment in ASCEND-NASH in the first quarter of 2024, and the initial subjects are now approaching the later stages of the 12-month trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.37 USD | +6.20% | -31.84% | -57.72% |
Apr. 22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
Apr. 22 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.72% | 7.5M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- HEPA Stock
- News Hepion Pharmaceuticals, Inc.
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat